ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

ABT-888 and mFOLFOX-6

ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3

Trial Locations (1)

20007

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

Georgetown University

OTHER

NCT01489865 - ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter